Medicine
Comparative Effectiveness of Immunotherapy Versus Chemotherapy in Non-Small Cell Lung Cancer
Quick fact
In clinical trials, immunotherapy (such as pembrolizumab) has shown a 5-year survival rate of about 31.9% for previously untreated advanced non-small cell lung cancer with high PD-L1 expression, compared to 16.3% with chemotherapy.
Why this is interesting
What if the body's own immune system could be trained to fight cancer more effectively than chemotherapy? In non-small cell lung cancer, that is now a reality—but it doesn't work for everyone.
Read the full explanation
Understanding Comparative Effectiveness of Immunotherapy Versus Chemotherapy in Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Historically, chemotherapy was the main treatment for advanced cases, but it works by killing rapidly dividing cells, which also damages healthy cells and causes side effects. Immunotherapy takes a different approach: it doesn't target the cancer directly. Instead, it 'releases the brakes' on the immune system, allowing T-cells to recognize and attack cancer cells. The key players are proteins like PD-1 on T-cells and PD-L1 on cancer cells. When PD-L1 binds to PD-1, it switches off the T-cell. Immunotherapy drugs block this interaction, so T-cells stay active. Effectiveness can be measured by how long patients live (overall survival) or how long the cancer stays controlled. In some patients, immunotherapy produces durable responses that last years, which is rare with chemotherapy.
A deeper explanation
The comparative effectiveness of immunotherapy versus chemotherapy is not a simple 'one is better' answer. It hinges on the tumor's biology, especially PD-L1 expression. When a tumor expresses high levels of PD-L1, it is exploiting the PD-1/PD-L1 pathway to evade immune attack. Blocking this pathway with an immune checkpoint inhibitor can reactivate T-cells, leading to tumor regression. This is why immunotherapy tends to be more effective in tumors with high PD-L1 expression. However, if a tumor has low PD-L1, the immune system may not be able to mount an effective response even without the brake, so chemotherapy might be more reliable. Additionally, immunotherapy can cause immune-related side effects (like inflammation of the lungs or colon) which are different from chemotherapy's side effects (like hair loss and nausea). The mechanism is not just about killing cells; it's about restoring immune surveillance. Importantly, some patients respond brilliantly, but others do not, so biomarkers like PD-L1 are used to guide treatment choices. The comparison is also about duration: chemotherapy often shrinks tumors quickly but the effect may be short-lived, while immunotherapy may take longer to show response but the response can be long-lasting.